Les investigadores Sonia Pernas i Marta Gil-Mart\u00edn, del programa de recerca Oncobell (Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u2013 Institut Catal\u00e0 d\u2019Oncologia (ICO)) condueixen a l\u2019ICO el primer assaig cl\u00ednic que prova amb \u00e8xit un nou tipus de f\u00e0rmac – un antagonista de CXCR4 – en pacients amb c\u00e1ncer de mama metast\u00e0tic HER2-negatiu. En base als resultats d\u2019aquest estudi, publicats a la prestigiosa revista The Lancet Oncology, la Food and Drug Administration d\u2019Estats Units ha atorgat la designaci\u00f3 \u201cFast track\u201d a aquesta nova ter\u00e0pia immuno-oncol\u00f2gica, fet que podr\u00e0 acelerar-ne el desenvolupament.<\/p>\n
\u201cEstem davant del primer assaig que investiga aquest tipus de ter\u00e0pia\u00a0 en pacients amb c\u00e0ncer de mama metast\u00e0sic\u201d, explica la Dra. Sonia Pernas, primera autora de l\u2019estudi.\u00a0 En aquest assaig, fase 1, els investigadors estableixen que la combinaci\u00f3 de balixafortida – antagonista del receptor CXCR4 – i eribulina t\u00e9 un perfil de seguretat favorable, similar al de cada f\u00e0rmac utilitzat per separat. <\/p>\n
\u00a0<\/p>\n
Pel que fa a l\u2019activitat antitumoral, els resultats de l\u2019estudi mostren el gran potencial d\u2019aquest f\u00e0rmac en combinaci\u00f3 amb eribulina (amb un 63% de benefici clinic, incloent un 38% de respostes objectives en pacients previament tractades amb entre 1 i 3 l\u00ednies de quimioterapia), com a nova opci\u00f3 terap\u00e8utica per pacients afectades amb c\u00e0ncer de mama metast\u00e0tic avan\u00e7at. \u00c9s per aquest motiu que la Food and Drug Administration nord-americana ha atorgat a la combinaci\u00f3 la designaci\u00f3 Fast-track per accelerar-ne la revisi\u00f3 i poder cobrir el m\u00e9s aviat possible aquesta necessitat m\u00e8dica no satisfeta.\u00a0 <\/p>\n
L\u2019assaig, desenvolupat en 11 centres arreu d\u2019Espanya i Estats Units, ha comptat amb 56 participants. \u201cEn aquest sentit, cal remarcar el paper de l’ICO\u00a0, ja que ha estat el centre on s\u2019han incl\u00f2s mes pacients\u201d, comenta la Dra. Pernas.<\/p>\n
CXCR4 \u00e9s un receptor que juga un paper cr\u00edtic en el creixement, la superviv\u00e8ncia, l’angiog\u00e8nesi i la met\u00e0stasi de tumors; se sap que una elevada expressi\u00f3 de CXCR4 correlaciona amb el comportament metast\u00e0tic agressiu de les c\u00e8l\u00b7lules canceroses i un mal pron\u00f2stic. La balixafortida \u00e9s l’\u00fanic antagonista de CXCR4 actualment en desenvolupament com a tractament pel c\u00e0ncer de mama. <\/p>\n
\u00a0<\/p>\n
Refer\u00e8ncia de l\u2019article<\/p>\n
Pernas, Sonia et al. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. The Lancet Oncology , Volume 19 , Issue 6 , 812 \u2013 824. doi: 10.1016\/S1470-2045(18)30147-5. <\/p>\n","protected":false},"excerpt":{"rendered":"
Les investigadores Sonia Pernas i Marta Gil-Mart\u00edn, del programa de recerca Oncobell (Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u2013 Institut Catal\u00e0 d\u2019Oncologia (ICO)) condueixen a l\u2019ICO el primer assaig cl\u00ednic que prova amb \u00e8xit un nou tipus de f\u00e0rmac – un antagonista de CXCR4 – en pacients amb c\u00e1ncer de mama metast\u00e0tic HER2-negatiu. En base […]<\/p>\n","protected":false},"author":6,"featured_media":10572,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-09 14:27:49","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7627"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7627"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7627\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10572"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}